Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Transplant Proc ; 50(5): 1276-1280, 2018 06.
Article in English | MEDLINE | ID: mdl-29880346

ABSTRACT

BACKGROUND: Pretransplant psychosocial evaluation of living-donor kidney transplantation (LDKT) candidates identifies recipients with potentially inferior posttransplant outcomes. Rating instruments, based on semi-standardized interviews, help to improve and standardize psychosocial evaluation. The goal of this study was to retrospectively investigate the correlation between the Transplant Evaluation Rating Scale (TERS) and transplant outcome in LDKT recipients. METHODS: TERS scores were retrospectively generated by 2 raters based on comprehensive interviews of 146 LDKT recipients conducted by mental health professionals (interrater reliability, 0.8-0.9). All patients were eligible for transplantation according to pretransplant psychosocial evaluation. Patients were classified into 2 groups according to their TERS scores, in either two thirds excellent risk (TERS <29) and one third at least moderate risk (TERS ≥29) candidates. Analyzed medical parameters were change in estimated glomerular filtration rate and acute rejection (AR) episodes within the first year posttransplant. In addition, a subgroup of 65 patients was tested for de novo donor-specific HLA antibodies (DSA) posttransplant. RESULTS: There was no significant difference between the excellent (n = 97) and at least moderate (n = 49) risk candidates according to TERS in terms of organ function (estimated glomerular filtration rate decline >25%: 17 of 97 vs 11 of 49; P = .51) and episodes of AR (19 of 97 vs 15 of 49; P = .15). Patients developing de novo DSA (n = 18 [28%]) did not have higher pretransplant TERS scores (DSA positive, 11 of 42 vs 7 of 23; P = .78). CONCLUSIONS: Classifying LDKT recipients according to TERS score did not predict medical outcome at 1 year posttransplant or the occurrence of de novo DSA.


Subject(s)
Graft Rejection/psychology , Kidney Transplantation/psychology , Living Donors , Postoperative Complications/psychology , Psychiatric Status Rating Scales/statistics & numerical data , Adult , Antibodies/blood , Antibodies/immunology , Female , Glomerular Filtration Rate , HLA Antigens/immunology , Humans , Male , Middle Aged , Postoperative Period , Reproducibility of Results , Retrospective Studies , Treatment Outcome
2.
Am J Transplant ; 17(2): 542-550, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27529836

ABSTRACT

Immunosuppressive strategies applied in renal transplantation traditionally focus on T cell inhibition. B cells were mainly examined in the context of antibody-mediated rejection, whereas the impact of antibody-independent B cell functions has only recently entered the field of transplantation. Similar to T cells, distinct B cell subsets can enhance or inhibit immune responses. In this study, we prospectively analyzed the evolution of B cell subsets in the peripheral blood of AB0-compatible (n = 27) and AB0-incompatible (n = 10) renal transplant recipients. Activated B cells were transiently decreased and plasmablasts were permanently decreased in patients without signs of rejection throughout the first year. In patients with histologically confirmed renal allograft rejection, activated B cells and plasmablasts were significantly elevated on day 365. Rituximab treatment in AB0-incompatible patients resulted in long-lasting B cell depletion and in a naïve phenotype of repopulating B cells 1 year following transplantation. Acute allograft rejection was correlated with an increase of activated B cells and plasmablasts and with a significant reduction of regulatory B cell subsets. Our study demonstrates the remarkable effects of standard immunosuppression on circulating B cell subsets. Furthermore, the B cell compartment was significantly altered in rejecting patients. A specific targeting of deleterious B cell subsets could be of clinical benefit in renal transplantation.


Subject(s)
ABO Blood-Group System/immunology , Blood Group Incompatibility/immunology , Graft Rejection/etiology , Graft Survival/immunology , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Transplant Recipients , Adult , B-Lymphocyte Subsets/immunology , Female , Follow-Up Studies , Graft Rejection/blood , Humans , Immunosuppressive Agents/therapeutic use , Living Donors , Male , Postoperative Complications , Prognosis , Prospective Studies , Risk Factors , Transplantation, Homologous
3.
Eur J Med Res ; 12(3): 134-8, 2007 Mar 26.
Article in English | MEDLINE | ID: mdl-17507310

ABSTRACT

BACKGROUND: During the last few years a number of previously undescribed viruses, including human metapneumovirus, coronaviruses SARS, NL63 and HKU1, and bocavirus, were identified in nasopharyngeal samples from patients with signs of respiratory infections. These viruses may cause mild to life-threatening infections. OBJECTIVES: Nasopharyngeal samples from hospitalized pediatric patients with respiratory disease were analysed for the presence of coronaviruses and other well known and newly identified respiratory viruses. RESULTS: Two clinical cases of a severe obstructive pneumonia, which were associated with the presence of RNA of a novel variant (subtype) of HKU1 coronavirus in the nasopharyngeal aspirates, were identified. DISCUSSION: The detection of a HKU1-like coronavirus in pediatric patients in the current study complement the most recent independent finding of similar or closely related coronaviruses in patients with respiratory diseases in France (Vabret et al. 2006) and Norway (Jonassen et al., see accompanying manuscript). These observations indicate a wide dissemination of HKU1-like coronaviruses in Europe.


Subject(s)
Coronavirus Infections/virology , Coronavirus/classification , Coronavirus/isolation & purification , Coronavirus/pathogenicity , Pneumonia, Viral/virology , Administration, Inhalation , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/administration & dosage , Adrenergic beta-Agonists/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/therapeutic use , Budesonide/administration & dosage , Budesonide/therapeutic use , Coronavirus/genetics , Hospitalization , Humans , Infant , Infusions, Intravenous , Ipratropium/administration & dosage , Ipratropium/therapeutic use , Length of Stay , Male , Nasopharynx/virology , Oxygen/administration & dosage , Oxygen/therapeutic use , Phylogeny , Pneumonia, Viral/drug therapy , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reagent Kits, Diagnostic , Reverse Transcriptase Polymerase Chain Reaction , Severity of Illness Index , Steroids/administration & dosage , Steroids/therapeutic use , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...